What does a FibroScan showing liver stiffness of 8.2 kPa and CAP score of 260 dB/m indicate, and what management is recommended?

FibroScan Results Interpretation: Liver Stiffness 8.2 kPa with CAP 260 dB/m

Your FibroScan shows borderline liver stiffness at the threshold for clinically significant fibrosis (8.2 kPa) and moderate hepatic steatosis (CAP 260 dB/m), placing you in an indeterminate risk category that requires hepatology referral for further evaluation and intensified metabolic risk factor management.

What These Numbers Mean

Liver Stiffness (8.2 kPa)

Your liver stiffness measurement sits precisely at the critical cutoff value. According to the 2021 AASLD/Gastroenterology clinical care pathway, 8.0-8.2 kPa represents the threshold between low-risk and indeterminate-risk categories 1. This value:

• Does NOT exclude clinically significant fibrosis (F2-F4) - you are above the <8.0 kPa threshold used to rule out significant disease
• Suggests possible F2 fibrosis (clinically significant) but does not confirm advanced fibrosis (F3-F4)
• Falls into the "gray zone" requiring additional evaluation 2

The 2022 AACE guidelines specifically recommend that patients with LSM 8.0-12.0 kPa fall into an indeterminate-risk group requiring hepatology referral 2.

CAP Score (260 dB/m)

Your CAP of 260 dB/m indicates moderate hepatic steatosis (S2). The validated cutoffs from the 2019 Gastroenterology study show 3:

• S1 (mild steatosis): 302 dB/m
• S2 (moderate): 331 dB/m
• S3 (severe): 337 dB/m

However, some studies use lower thresholds, with CAP >260 dB/m defining moderate-to-severe steatosis 4. Your value sits right at this boundary, confirming at least moderate fat accumulation in your liver.

Recommended Management Algorithm

Step 1: Calculate FIB-4 Score (If Not Already Done)

The 2024 EASL-EASD-EASO guidelines mandate a two-tier approach 5:

• First tier: FIB-4 score (uses age, AST, ALT, platelets)
• Second tier: Liver stiffness measurement (which you've completed)

If your FIB-4 is:

• <1.3 (age ≤65) or <2.0 (age >65): Combined with your borderline LSM, suggests lower risk but still warrants monitoring
• 1.3-2.67: Confirms indeterminate risk requiring hepatology referral
• >2.67: High risk requiring immediate hepatology referral 1, 5

Step 2: Hepatology Referral

You should be referred to a hepatologist based on current guidelines 2. The hepatologist will likely:

1. Consider additional testing 1:

   • Enhanced Liver Fibrosis (ELF) blood test
   • Magnetic Resonance Elastography (MRE) - more accurate than FibroScan, with cutoff ≥3.3 kPa for F2+ fibrosis
   • Possibly liver biopsy if results remain indeterminate

2. Evaluate for underlying causes:

   • Metabolic syndrome components (diabetes, obesity, hypertension, dyslipidemia)
   • Alcohol use
   • Viral hepatitis (HBV, HCV)
   • Other liver diseases 6

Step 3: Intensified Metabolic Management (Start Immediately)

Do not wait for hepatology appointment to begin lifestyle modifications 5:

• Weight loss target: ≥7-10% body weight loss can improve both steatosis and fibrosis
• Dietary changes: Mediterranean diet, reduce refined carbohydrates and saturated fats
• Physical activity: 150+ minutes/week moderate-intensity exercise
• Optimize metabolic comorbidities:
  • Tight glycemic control if diabetic (consider GLP-1 receptor agonists - they have liver benefits)
  • Treat hypertension and dyslipidemia aggressively
  • Address insulin resistance

Step 4: Surveillance Schedule

Based on your indeterminate risk status 1:

• Repeat FibroScan in 6-12 months to assess response to interventions
• Studies show that one-third of patients with LSM >12 kPa show reversal after 4-6 months with lifestyle changes 7
• Weight loss ≥1 kg and increased physical activity significantly reduce both LSM and CAP scores 7

Critical Caveats

Factors That Can Falsely Elevate Your LSM

Your 8.2 kPa reading may be influenced by 8:

• Recent food intake - should be fasting ≥2 hours
• Elevated liver enzymes/ALT flares - inflammation increases stiffness independent of fibrosis
• Alcohol consumption - even moderate intake within days of test
• Extrahepatic cholestasis
• Congestive heart failure

If any of these apply, repeat the FibroScan under optimal conditions before making definitive management decisions.

Why 8.2 kPa Is Not Definitive for Advanced Fibrosis

The 2021 Gastroenterology pathway emphasizes that LSM <8.2 kPa excludes advanced fibrosis (F3-F4) with >80% negative predictive value 1. However, your value sits exactly at this threshold, meaning:

• You likely do NOT have advanced fibrosis/cirrhosis
• You MAY have clinically significant fibrosis (F2)
• The positive predictive value at this cutoff is only 78% in diabetes clinics and 97% in general population 1

Steatosis Does Not Significantly Affect LSM

Multiple studies confirm that steatosis itself does not meaningfully increase liver stiffness measurements - your 8.2 kPa reflects fibrosis risk, not just fat 3. This is important because it means your borderline stiffness cannot be dismissed as simply due to fatty liver.

Bottom Line

Your results indicate metabolic dysfunction-associated steatotic liver disease (MASLD) with moderate steatosis and possible early clinically significant fibrosis. You are not in the low-risk category that can be managed with surveillance alone, nor are you in the high-risk category with probable advanced fibrosis. This indeterminate status requires:

1. Hepatology referral for additional testing (ELF, possibly MRE or biopsy)
2. Immediate aggressive lifestyle intervention - weight loss and exercise can reverse both steatosis and early fibrosis
3. Optimization of all metabolic risk factors in coordination with your primary care provider or endocrinologist
4. Repeat assessment in 6-12 months to document response

The good news: at this stage, liver fibrosis is potentially reversible with sustained lifestyle changes and metabolic control 1, 7.